High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: Clinical and cytokine correlations

Rheumatology International

Volumn 28, Issue 10, 2008, Pages 979-986

  O'Rourke, Killian P ^a,c   O'Donoghue, G ^a   Adams, C ^a   Mulcahy, H ^a   Molloy, C ^a   Silke, C ^b   Molloy, M ^b   Shanahan, F ^b   O'Gara, F ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

^c MUSGROVE PARK HOSPITAL   (United Kingdom)

Author keywords

Arthritis; LT Beta; Lymphotoxin; Rheumatoid; Synovium

Indexed keywords

LYMPHOTOXIN; LYMPHOTOXIN BETA; LYMPHOTOXIN BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; GENE; GENE EXPRESSION PROFILING; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN TISSUE; INFLAMMATION; LT ALPHA GENE; LT BETA GENE; LT BETAR GENE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIUM; TNF ALPHA GENE; VISUAL ANALOG SCALE;

ARTHRITIS, RHEUMATOID; GENE EXPRESSION; HUMANS; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-ALPHA; LYMPHOTOXIN-BETA; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47249117031     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0574-z     Document Type: Article

References (37)

1. Seldin MF, Amos CI, Ward R, Gregersen PK (1999) The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 42:1071-1079
2. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440
3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. NEJM 340:253-259
4. Browning JL, Ngam-ek A, Lawton P, DeMarinis J, Tizard R, Chow EP et al (1993) Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 26:847-856
5. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL (2002) Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, Lymphotoxin-[alpha]1[beta]2, fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 168:1831-1839
6. Agyekum S, Church A, Sohail M, Krausz T, Van Noorden S, Polak J et al (2003) Expression of lymphotoxin-beta (LT-Beta) in chronic inflammatory conditions. J Pathol 199:115-21
7. Shlopov BV, Gumanovskaya ML, Hasty KA (2000) Autocrine regulation of collagenase 3 (Matrix Metallo Proteinase 13) during osteoarthritis. Arthritis Rheum 43:195-205
8. Mackay F, Majeau GR, Hochman PS, Browning JL. (1996) Lymphotoxin beta receptor triggering induces activation of the nuclear factor kappaB transcription factor in some cell types. J Biol Chem 271:24934-8
9. Mulcahy B, Waldron-Lynch F, McDermott MF, Adams C, Amos CI, Zhu DK, Ward RH, Clegg DO, Shanahan F, Molloy MG, O'Gara F (1996) Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 59(3):676-683
10. Newton JL, Harney SM, Wordsworth BP, Brown MA (2004) A review of the MHC genetics of rheumatoid arthritis. Genes Immun 5:151-157
11. Mandik-Nayak L, Wipke BT, Shih FF, Unanue ER, Allen PM (2002) Despite ubiquitous autoantigen expression arthrogenic autoantibody response initiates in the local lymph node. PNAS 99:14368-14373
12. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM et al (2001) Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167:1072-1080
13. Rennert PD, James D, Mackay F, Browning JL, Hochman PS (1998) Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 9:71-79
14. Ramey DR, Raynaud JP, Fries JF (1992) The health assessment questionnaire 1992: status and review. Arthritis Care Res 5:119-129
15. Anderson JJ, Chernoff MC (1993) Sensitivity to change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol 20:535-537
16. Young CL, Adamson TC, Vaughan JH, Fox RI (1984) Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum 27:32-39
17. Krenn V, Souto-Carneiro MM, Kim HJ, Berek C, Starostik P, Konig A et al (2000) Hitopathology and molecular pathology of synovial B-lymphocytes in rheumatoid arthritis. Histol Histopathol 15:791-798
18. Koizumi F, Matsuno H, Wakaki K, Ishii Y, Kurashige Y, Nakamura H (1999) Synovitis in rheumatoid arthritis: scoring of characteristic histopathological features. Pathol Int 49:298-304
19. Raff T, Van der Giet M, Endemann D, Wiederholt T, Paul M (1997) Design and testing of beta-actin primers for RT-PCR that do not co-amplify pseudogenes. Biotechniques 23:456-460
20. Braun A, Takemura S, Vallejo AN, Goronzy JJ, Weyand CM (2004) Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 50:2140-2150
21. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD et al (2000) A Chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406:309-314
22. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S et al (2002) Is NFkB a useful therapeutic target in rheumatoid arthritis. Ann Rheum Dis 61(Suppl 2):13-18
23. Kuprash DV, Osipovich OA, Pokholok DK, Alimzhanov MB, Biragyn A, Turetskaya RL et al (1996) Functional analysis of the lymphotoxin-B promoter. J Immunol 156:2465-2472
24. Voon DC, Subrata LS, Abraham LJ (2001) Regulation of lymphotoxin-beta by tumor necrosis factor, phorbol myristate acetate, and ionomycin in Jurkat T cells. J Interferon Cytokine Res 21:921-930
25. Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA (1990) Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 33:542-552
26. Thomson BM, Mundy GR, Chambers TJ (1987) Tumour necrosis factor alpha and beta induce osteoblastic cells to stimulate osteoclast bone resorption. J Immunol 138:775-779
27. Kowanko IC, Bates EJ, Ferrante A (1988) Tumour necrosis factor-beta modulates human neutrophil-mediated cartilage damage. Scand J Immunol 28:591-598
28. Kuprash DV, Boitchenko VE, Yarovinsky FO, Rice NR, Nordheim A, Ruhlmann A et al (2002) Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta in human peripheral blood mononuclear cells. Blood 100:1721-1727
29. Ettinger R (2000) The role of tumour necrosis factor and lymphotoxin in lymphoid organ development. Curr Top Microbiol Immunol 251:203-210
30. Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell B (2001) NK-kB-inducing kinase is dispensible for activation of NF-kB in inflammatory settings but essential for lymphotoxin B receptor activation of NFkB in primary human fibroblasts. J Immunol 167:5895-5903
31. Husson H, Lugli SM, Ghia P, Cardosso A, Roth A, Brohmi K et al (2000) Functional effects of TNF and lymphotoxin alpha1beta2 on FDC-like cells. Cell Immunol 203:134-143
32. Arend WP, Dayer J-M (1990) Cytokine and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305-315
33. Drouet C, Shahhov AN, Jongeneel CV (1991) Enhancers and transcription factors controlling inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol 147:1694-1700
34. Kidd B (2004) What lessons can we learn from the study of pain pathways in rheumatic disease? J RCPE 34:66-67
35. Wu Q, Saloman B, Chen M, Wang Y, Hoffman LM, Bluestone JA et al (2001) Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med 193:1327-1332
36. Mackay F, Browning JL, Lawton P, Shah SA, Comiskey M, Bhan AK et al (1998) Both the lymphotoxin and tumour necrosis pathways are involved in experimental murine models of colitis. Gastroenterology 115:1464-1475
37. Tamada K, Tamura H, Flies D, Fu YX, Celis E, Pease LR et al (2002) Blockage of LIGHT / Ltbeta and CD 40 signalling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 109:549-557